Page 4 - Indian Pharma

Aurobindo Pharma net profit dips 22% to Rs 604 cr in December quarter

The Hyderabad-based drug maker had reported a consolidated net profit of Rs 777.3 crore in the same period of previous fiscal

Glenmark gets nod from US Food & Drug Administration for generic drug

Glenmark Pharmaceuticals on Friday said its US-based unit has received approval from the US health regulator to market Metronidazole Vaginal gel, in the American market. The drug firm has received final approval by the United States Food & Drug Administration (USFDA) for its product which is a generic version of Bausch Health US LLC's MetroGel-Vaginal, the drug firm said in a statement. According to IQVIA sales data for the 12-month period ending November 2021, the MetroGel-Vaginal Gel achieved annual sales of approximately around USD 60.4 million. Glenmark's current portfolio consists of 173 products authorised for distribution in the US marketplace and 46 ANDA's pending approval with the USFDA. In addition to these internal filings, the drug firm continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, Glenmark noted.

Hyderabad's Biophore to manufacture ingredients of Pfizer's Covid drug

Biophore India Pharmaceutical announced that it developed and started manufacturing the key intermediates of Nirmatrelvir, one of the active ingredients of Paxlovid, the latest anti-Covid therapy

2021 saw greater collaboration among pharma, govt, academia: Sudarshan Jain

'Diversified supply chain is a fundamental need', said Jain

New-age pharmacy start-ups tap 'kirana' networks, eye US market

New entrants in the largely unorganised Indian pharmaceuticals market are trying out innovative ways to tap a vast market that lies in hinterland

Amid $126-mn target, Indian pharma exporters stare at Afghan uncertainty

As uncertainty looms large in Afghanistan, Indian pharma exporters are apprehensive to send goods to the war-torn country

Intense price competition in US generics market hits Indian pharma

Players say low prescription, double-digit price erosion are key reasons

Dr Reddy's to sell US, Canada territory rights for migraine drug to BDSI

Drug firm Dr Reddy's Laboratories on Wednesday said it has entered into a definitive agreement with BioDelivery Sciences International, Inc., to sell its US and Canada territory rights

Small contract manufacturers wait to take a shot at Covid vaccines

A host of lesser-known vaccine makers are eyeing contract manufacturing opportunities for global and domestic majors

Can produce 250 mn doses of Sputnik V every year: Morepen India CMD

The approval of samples, licensing, and final production will take around two months and the vaccine would be available in India for sale also in two months, says CMD Sushil Suri

Pharma majors join hands for Molnupiravir trial for Covid-19 treatment

Leading drug makers have decided to collaborate for clinical trial of the investigational oral antiviral drug Molnupiravir

Manufacturers look to boost capacity as govt enhances vaccination scope

Firms work to secure raw material locally as imports remain a challenge

Indian pharma exports grow at 18% to $24.44 billion in FY 21 from $20.58 bn

Pharma exports from India witnessed over 18 per cent growth to USD 24.44 billion during the last financial year against USD 20.58 billion in FY20

Best of BS Opinion: A change in direction, healing a weak regulator & more

Here's a selection of Business Standard opinion pieces for the day

Indian pharma firms go local seeking to end reliance on China

Disruption to supplies from China due to the Covid-19 pandemic was also a major factor

Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost

Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities

Indian exports show signs of revival, up 16.2% to $6.2 bn in Jan first week

Exports grew 16.22 per cent year-on-year to $6.21 billion in the first week of January, mainly driven by healthy growth in pharmaceuticals, and engineering sectors, reflecting signs of revival

V G Somani: The DCGI chief, a man known by his actions, 'not of words'

To the media, Somani may be a man of few words but among peers he's known for quick responses

It's raining billionaires in India's pharma and health care space

Created 7 billionaires in 2020; now 17 super-rich promoters in the sector with combined wealth of Rs 4.35 trillion

A shot at transparency

Approval to Covaxin raises many questions